Navigation Links
DelMar Pharmaceuticals To Present At The 15th Annual Rodman & Renshaw Global Investment Conference
Date:9/3/2013

VANCOUVER, British Columbia and MENLO PARK, Calif., Sept. 3, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc., (OTCQB: DMPI), developer of advanced cancer therapeutics, will be featured as a presenting company at the 15th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC.  The presentation will take place Monday, September 9th at 3:15 p.m. EDT in Room 7.02 at the Millennium Broadway Hotel in New York City.  The presentation will be webcast live at http://wsw.com/webcast/rrshq23/DMPI and available for 90 days.

Jeffrey Bacha, president and CEO of DelMar, will provide an overview of DelMar's timely progress in developing important, new chemotherapies for patients who have little to no therapeutic options. 

DelMar's lead drug, VAL-083, is being developed to treat glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. VAL-083 is approved in China to treat chronic myelogenous leukemia and lung cancer and has received orphan drug designation in Europe and in the United States.

Developing Essential New Treatments for Aggressive Brain Cancers

Fifty percent of patients with GBM will fail today's approved therapies, Temodar® and Avastin®.  Tumor resistance to Temodar is well documented and known to be caused by the MGMT enzyme. Studies by the National Cancer Institute and DelMar have shown that VAL-083 acts through a unique mechanism unaffected by MGMT and has activity against a range of cancers. 

DelMar is conducting a Phase I/II clinical trial to assess the safety and efficacy of VAL-083 as
'/>"/>

SOURCE DelMar Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. DelMar Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
2. DelMar Pharmaceuticals Presents Additional Clinical Data from Ongoing Brain Cancer Study at ASCO
3. DelMar Pharmaceuticals, Inc. to Webcast, Live, at RetailInvestorConferences.com June 6th
4. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
5. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
6. DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
7. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
8. DelMar Pharma Named to Rocket Builders 2013"Ready to Rocket" List
9. DelMar Pharmaceuticals to Present at the 25th Annual ROTH Capital Partners Growth Stock Conference
10. DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering And Appointment Of Investor Relations Consultant
11. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... SANTA BARBARA, Calif. , Dec. 23, 2014 ... the Junior Doctors, Association of Sierra Leone ... Sierra Leone for the treatment of local ... While a new dedicated Ebola care center was ... Ebola virus, the facility is not available for local Sierra ...
(Date:12/22/2014)... Mass. , Dec. 22, 2014 ... leading manufacturer of innovative dialysis products, announced today ... has cleared its System One™ to perform hemodialysis ... known as home nocturnal hemodialysis. NxStage,s® System One ... by the FDA for this indication. ...
(Date:12/22/2014)... , Dec. 22, 2014 Research and ... the addition of the "Investment Analysis of ... to their offering. ... in the US medical device sector identifies the ... and venture capital investments, and mergers and acquisitions. ...
Breaking Medicine Technology:First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3Investment Analysis of the US Medical Device Sector 2
... Par Pharmaceutical Companies, Inc. (NYSE: PRX ... products from Teva Pharmaceuticals in connection with Teva,s acquisition ... own the ANDAs of fentanyl citrate lozenges, a generic ... version of Amrix®, as well as the U.S. rights ...
... 18, 2011 Tourists visiting the "Happiest Place on ... not able to experience it. Not all guests visiting ... walk the theme parks. Some people may appear healthy ... walking for long periods of time. Conditions stemming from ...
Cached Medicine Technology:Par Pharmaceutical Acquires Three Generic Products From Teva Pharmaceuticals 2
(Date:12/25/2014)... 25, 2014 (HealthDay News) -- The risk of burns ... so you need to be extra cautious, an expert ... see a significant increase in patients coming in with ... Suffolk County Volunteer Firefighters Burn Center of Stony Brook ... be full of joy, but if not careful, could ...
(Date:12/25/2014)... Dennis Thompson HealthDay ... Researchers could be closing in on a "fountain of youth" ... the health of older adults, a new study suggests. ... given a drug that targets a genetic signaling pathway linked ... Novartis report. The experimental medication, a version ...
(Date:12/25/2014)... “ SmileStix ” was featured on NewsWatch ... and coolest mobile applications on the iOS, Android, and Windows ... NewsWatch, conducted the app review and shared with viewers how ... , The old saying goes, “A picture says a thousand ... can describe a single image, because each picture holds a ...
(Date:12/25/2014)... CA (PRWEB) December 25, 2014 Each ... visits and 2 million hospital admissions across the nation ... Prevention ). The CDC’s National Hospital Ambulatory Medical ... through a survey conducted in 2010. They estimated that ... visits that resulted in a primary diagnosis of broken ...
(Date:12/24/2014)... December 25, 2014 Over 700 toys, ... their local communities. That is 700 smiling little faces ... gift. Additionally over $6000 in monetary donations was given ... some of the expenses they incur through the year. ... were A Child's Haven , Shrine's Children's Hospitals, ...
Breaking Medicine News(10 mins):Health News:Don't Let Burns Mar Your Holidays 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:AlignLife Donates Over 700 Toys This Year 2
... , PROVO, Utah , Jan. 19 ... announced that it will release fourth quarter financial results prior to the ... Hunt , president and chief executive officer, will host a conference call ... a.m. (EDT) . During the call, participants can expect to hear management ...
... , ANN ARBOR, Mich. , ... and MEDITECH have collaborated to offer content from the Micromedex ... Care Information System (HCIS) — Emergency Department Management, Physician Care ... one of the Micromedex clinical evidence solutions from Thomson Reuters, ...
... , ATLANTA , Jan. 19 ... of the Unit of Interventional Radiology at the European Institute ... 2010 Best Poster Award by Dr. Shaun Samuels , ... Embolization Combined with Radiofrequency Ablation for Treating Complex Hepatic Tumors. ...
... health care, particularly at the end of life, may incite ... Hopkins emeritus professor of neurology called for the start of ... month,s issue of the Journal of Medical Ethics . ... Emeritus of Pediatric Neurology and a faculty member of the ...
... infection, researchers find , TUESDAY, Jan. 19 (HealthDay News) -- ... treatment for sickle cell disease, a common genetic disorder, new ... in the Journal of Clinical Investigation , are based ... with the disease will benefit from treatment with statins. ...
... chromosome component, research shows , TUESDAY, Jan. 19 (HealthDay ... of the reasons why omega-3 fatty acids are good for ... heart disease consumed, the slower their telomeres shrank. Telomeres are ... the more times a cell divides, making them a marker ...
Cached Medicine News:Health News:Nu Skin Enterprises to Announce Fourth Quarter and Annual 2009 Results 2Health News:Micromedex CareNotes Available Within the MEDITECH Health Care Information System 2Health News:Micromedex CareNotes Available Within the MEDITECH Health Care Information System 3Health News:Orsi Awarded First Place for Procedure with Embozene(TM) Microspheres 2Health News:Reasoning through the rationing of end-of-life care 2Health News:Shedding Light on Why Omega-3 Fatty Acids May Help the Heart 2Health News:Shedding Light on Why Omega-3 Fatty Acids May Help the Heart 3
0.3% Yeast Extract, 0.3% Malt Extract, 0.5% Peptone, and 1.0% Glucose....
Tryptone is the pancreatic digest of casein used as a nitrogen source for bacteria. Ideal for general bacteriological use with a variety of microorganisms. Tryptone is guaranteed BSE-Free....
Penicillin G (1 x 10 4 units/mL and Streptomycin (10mg/mL) Solution. 100X Concentrate....
... units Penicillin/25,000 ug Streptomycin ... and Buffer products are manufactured ... and are cell culture tested ... Properties, Sterility : Neg. , ...
Medicine Products: